
-
Rain Therapeutics NasdaqGM:RAIN Rain Enhancement Technologies Holdco, Inc. develops, manufactures, and commercializes ionization rainfall generation technology. It plans to develop improvements on existing rainfall generation technologies by introducing robust measurement tools, including software monitoring technology, machine learning, rain gauges, and weather stations. The company was founded in 2022 and is headquartered in Naples, Florida.
Location: 4851 Tamiami Trail N, Naples, FL, 34103, United States | Website: https://rainwatertech.com | Industry: Pollution & Treatment Controls | Sector: Industrials
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
48.8M
Cash
32.6K
Avg Qtr Burn
-330.6K
Short % of Float
2.78%
Insider Ownership
71.60%
Institutional Own.
11.86%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Milademetan (RAIN-32) w/ atezolizumab Details Solid tumor/s, Cancer | Failed Discontinued | |
Milademetan (Rain-32) Details Solid tumor/s, Cancer, Carcinoma , Metastatic merkel cell carcinoma | Failed Discontinued | |
Milademetan (Rain-32) Details Liposarcoma, Cancer, Solid tumor/s | Failed Discontinued | |
Milademetan (RAIN-32) Details Solid tumor/s, Cancer | Failed Discontinued |